Cargando…
European survey on efficacy and safety of duty-cycled radiofrequency ablation for atrial fibrillation
AIMS: Duty-cycled radiofrequency ablation (RFA) has been used for atrial fibrillation (AF) for around 5 years, but large-scale data are scarce. The purpose of this survey was to report the outcome of the technique. METHODS AND RESULTS: A survey was conducted among 20 centres from seven European coun...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3501283/ https://www.ncbi.nlm.nih.gov/pubmed/22772054 http://dx.doi.org/10.1093/europace/eus188 |
_version_ | 1782250173382000640 |
---|---|
author | Scharf, C. Ng, G.A. Wieczorek, M. Deneke, T. Furniss, S.S. Murray, St. Debruyne, Ph. Hobson, N. Berntsen, R.F. Schneider, M.A. Hauer, H.A. Halimi, F. Boveda, S. Asbach, S. Boesche, L. Zimmermann, M. Brigadeau, F. Taieb, J. Merkel, M. Pfyffer, M. Brunner-La Rocca, H.P. Boersma, L.V.A. |
author_facet | Scharf, C. Ng, G.A. Wieczorek, M. Deneke, T. Furniss, S.S. Murray, St. Debruyne, Ph. Hobson, N. Berntsen, R.F. Schneider, M.A. Hauer, H.A. Halimi, F. Boveda, S. Asbach, S. Boesche, L. Zimmermann, M. Brigadeau, F. Taieb, J. Merkel, M. Pfyffer, M. Brunner-La Rocca, H.P. Boersma, L.V.A. |
author_sort | Scharf, C. |
collection | PubMed |
description | AIMS: Duty-cycled radiofrequency ablation (RFA) has been used for atrial fibrillation (AF) for around 5 years, but large-scale data are scarce. The purpose of this survey was to report the outcome of the technique. METHODS AND RESULTS: A survey was conducted among 20 centres from seven European countries including 2748 patients (2128 with paroxysmal and 620 with persistent AF). In paroxysmal AF an overall success rate of 82% [median 80%, interquartile range (IQR) 74–90%], a first procedure success rate of 72% [median 74% (IQR 59–83%)], and a success of antiarrhythmic medication of 59% [median 60% (IQR 39–72%)] was reported. In persistent AF, success rates were significantly lower with 70% [median 74% (IQR 60–92%)]; P = 0.05) as well as the first procedure success rate of 58% [median 55% (IQR 47–81%)]; P = 0.001). The overall success rate was similar among higher and lower volume centres and were not dependent on the duration of experience with duty-cycled RFA (r = −0.08, P = 0.72). Complications were observed in 108 (3.9%) patients, including 31 (1.1%) with symptomatic transient ischaemic attack or stroke, which had the same incidence in paroxysmal and persistent AF (1.1 vs. 1.1%) and was unrelated to the case load (r = 0.24, P = 0.15), bridging anticoagulation to low molecular heparin, routine administration of heparin over the long sheath, whether a transoesophageal echocardiogram was performed in every patient or not and average procedure times. CONCLUSION: Duty-cycled RFA has a self-reported success and complication rate similar to conventional RFA. After technical modifications a prospective registry with controlled data monitoring should be conducted to assess outcome. |
format | Online Article Text |
id | pubmed-3501283 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-35012832012-11-19 European survey on efficacy and safety of duty-cycled radiofrequency ablation for atrial fibrillation Scharf, C. Ng, G.A. Wieczorek, M. Deneke, T. Furniss, S.S. Murray, St. Debruyne, Ph. Hobson, N. Berntsen, R.F. Schneider, M.A. Hauer, H.A. Halimi, F. Boveda, S. Asbach, S. Boesche, L. Zimmermann, M. Brigadeau, F. Taieb, J. Merkel, M. Pfyffer, M. Brunner-La Rocca, H.P. Boersma, L.V.A. Europace Clinical Research AIMS: Duty-cycled radiofrequency ablation (RFA) has been used for atrial fibrillation (AF) for around 5 years, but large-scale data are scarce. The purpose of this survey was to report the outcome of the technique. METHODS AND RESULTS: A survey was conducted among 20 centres from seven European countries including 2748 patients (2128 with paroxysmal and 620 with persistent AF). In paroxysmal AF an overall success rate of 82% [median 80%, interquartile range (IQR) 74–90%], a first procedure success rate of 72% [median 74% (IQR 59–83%)], and a success of antiarrhythmic medication of 59% [median 60% (IQR 39–72%)] was reported. In persistent AF, success rates were significantly lower with 70% [median 74% (IQR 60–92%)]; P = 0.05) as well as the first procedure success rate of 58% [median 55% (IQR 47–81%)]; P = 0.001). The overall success rate was similar among higher and lower volume centres and were not dependent on the duration of experience with duty-cycled RFA (r = −0.08, P = 0.72). Complications were observed in 108 (3.9%) patients, including 31 (1.1%) with symptomatic transient ischaemic attack or stroke, which had the same incidence in paroxysmal and persistent AF (1.1 vs. 1.1%) and was unrelated to the case load (r = 0.24, P = 0.15), bridging anticoagulation to low molecular heparin, routine administration of heparin over the long sheath, whether a transoesophageal echocardiogram was performed in every patient or not and average procedure times. CONCLUSION: Duty-cycled RFA has a self-reported success and complication rate similar to conventional RFA. After technical modifications a prospective registry with controlled data monitoring should be conducted to assess outcome. Oxford University Press 2012-12 2012-07-06 /pmc/articles/PMC3501283/ /pubmed/22772054 http://dx.doi.org/10.1093/europace/eus188 Text en Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2012. For permissions please email: journals.permissions@oup.com. http://creativecommons.org/licenses/by-nc/2.0/uk/ The online version of this article has been published under an open access model. Users are entitled to use, reproduce, disseminate, or display the open access version of this article for non-commercial purposes provided that the original authorship is properly and fully attributed; the Journal, Learned Society and Oxford University Press are attributed as the original place of publication with correct citation details given; if an article is subsequently reproduced or disseminated not in its entirety but only in part or as a derivative work this must be clearly indicated. For commercial re-use, please contact journals.permissions@oxfordjournals.org. |
spellingShingle | Clinical Research Scharf, C. Ng, G.A. Wieczorek, M. Deneke, T. Furniss, S.S. Murray, St. Debruyne, Ph. Hobson, N. Berntsen, R.F. Schneider, M.A. Hauer, H.A. Halimi, F. Boveda, S. Asbach, S. Boesche, L. Zimmermann, M. Brigadeau, F. Taieb, J. Merkel, M. Pfyffer, M. Brunner-La Rocca, H.P. Boersma, L.V.A. European survey on efficacy and safety of duty-cycled radiofrequency ablation for atrial fibrillation |
title | European survey on efficacy and safety of duty-cycled radiofrequency ablation for atrial fibrillation |
title_full | European survey on efficacy and safety of duty-cycled radiofrequency ablation for atrial fibrillation |
title_fullStr | European survey on efficacy and safety of duty-cycled radiofrequency ablation for atrial fibrillation |
title_full_unstemmed | European survey on efficacy and safety of duty-cycled radiofrequency ablation for atrial fibrillation |
title_short | European survey on efficacy and safety of duty-cycled radiofrequency ablation for atrial fibrillation |
title_sort | european survey on efficacy and safety of duty-cycled radiofrequency ablation for atrial fibrillation |
topic | Clinical Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3501283/ https://www.ncbi.nlm.nih.gov/pubmed/22772054 http://dx.doi.org/10.1093/europace/eus188 |
work_keys_str_mv | AT scharfc europeansurveyonefficacyandsafetyofdutycycledradiofrequencyablationforatrialfibrillation AT ngga europeansurveyonefficacyandsafetyofdutycycledradiofrequencyablationforatrialfibrillation AT wieczorekm europeansurveyonefficacyandsafetyofdutycycledradiofrequencyablationforatrialfibrillation AT deneket europeansurveyonefficacyandsafetyofdutycycledradiofrequencyablationforatrialfibrillation AT furnissss europeansurveyonefficacyandsafetyofdutycycledradiofrequencyablationforatrialfibrillation AT murrayst europeansurveyonefficacyandsafetyofdutycycledradiofrequencyablationforatrialfibrillation AT debruyneph europeansurveyonefficacyandsafetyofdutycycledradiofrequencyablationforatrialfibrillation AT hobsonn europeansurveyonefficacyandsafetyofdutycycledradiofrequencyablationforatrialfibrillation AT berntsenrf europeansurveyonefficacyandsafetyofdutycycledradiofrequencyablationforatrialfibrillation AT schneiderma europeansurveyonefficacyandsafetyofdutycycledradiofrequencyablationforatrialfibrillation AT hauerha europeansurveyonefficacyandsafetyofdutycycledradiofrequencyablationforatrialfibrillation AT halimif europeansurveyonefficacyandsafetyofdutycycledradiofrequencyablationforatrialfibrillation AT bovedas europeansurveyonefficacyandsafetyofdutycycledradiofrequencyablationforatrialfibrillation AT asbachs europeansurveyonefficacyandsafetyofdutycycledradiofrequencyablationforatrialfibrillation AT boeschel europeansurveyonefficacyandsafetyofdutycycledradiofrequencyablationforatrialfibrillation AT zimmermannm europeansurveyonefficacyandsafetyofdutycycledradiofrequencyablationforatrialfibrillation AT brigadeauf europeansurveyonefficacyandsafetyofdutycycledradiofrequencyablationforatrialfibrillation AT taiebj europeansurveyonefficacyandsafetyofdutycycledradiofrequencyablationforatrialfibrillation AT merkelm europeansurveyonefficacyandsafetyofdutycycledradiofrequencyablationforatrialfibrillation AT pfyfferm europeansurveyonefficacyandsafetyofdutycycledradiofrequencyablationforatrialfibrillation AT brunnerlaroccahp europeansurveyonefficacyandsafetyofdutycycledradiofrequencyablationforatrialfibrillation AT boersmalva europeansurveyonefficacyandsafetyofdutycycledradiofrequencyablationforatrialfibrillation |